Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P. Pignot G, et al. Among authors: borchiellini d. World J Urol. 2025 Jan 2;43(1):54. doi: 10.1007/s00345-024-05361-y. World J Urol. 2025. PMID: 39747746
Sex Disparities in Bladder Cancer Diagnosis and Treatment.
Pignot G, Barthélémy P, Borchiellini D. Pignot G, et al. Among authors: borchiellini d. Cancers (Basel). 2024 Dec 7;16(23):4100. doi: 10.3390/cancers16234100. Cancers (Basel). 2024. PMID: 39682286 Free PMC article. Review.
Perioperative immunotherapy in renal cell carcinoma.
Borchiellini D, Bensalah K. Borchiellini D, et al. Lancet Oncol. 2024 Aug;25(8):950-951. doi: 10.1016/S1470-2045(24)00268-7. Epub 2024 Jun 25. Lancet Oncol. 2024. PMID: 38942045 No abstract available.
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Chamorey E, Pujalte-Martin M, Ferrero JM, Mahammedi H, Gravis G, Roubaud G, Beuzeboc P, Largillier R, Borchiellini D, Linassier C, Bouges H, Etienne-Grimaldi MC, Schiappa R, Gal J, Milano G. Chamorey E, et al. Among authors: borchiellini d. Int J Mol Sci. 2024 May 31;25(11):6058. doi: 10.3390/ijms25116058. Int J Mol Sci. 2024. PMID: 38892246 Free PMC article.
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albigès L. Carril-Ajuria L, et al. Among authors: borchiellini d. Eur J Cancer. 2024 Jun;204:114048. doi: 10.1016/j.ejca.2024.114048. Epub 2024 Apr 8. Eur J Cancer. 2024. PMID: 38653033
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi AL, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Gonçalves LCP, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M. Montemagno C, et al. Among authors: borchiellini d. J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2. J Exp Clin Cancer Res. 2024. PMID: 38504270 Free PMC article.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, Escudier B, Flippot R, Albiges L. Mourey L, et al. Among authors: borchiellini d. Eur J Cancer. 2024 Apr;201:113589. doi: 10.1016/j.ejca.2024.113589. Epub 2024 Feb 3. Eur J Cancer. 2024. PMID: 38382153
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI. Plimack ER, et al. Among authors: borchiellini d. Eur Urol. 2024 Feb;85(2):e58-e59. doi: 10.1016/j.eururo.2023.11.016. Epub 2023 Dec 8. Eur Urol. 2024. PMID: 38071169 No abstract available.
88 results